Bioventix Plc was founded in 2003, following a management buyout (MBO). Based in Farnham it’s a biotechnology company specialising in the manufacture and supply of high affinity sheep monoclonal antibodies (SMAs) for use in immunodiagnostics. The company is run by its CEO, Peter Harrison, who led the 2003 MBO. Peter has extensive experience of the development and commercialisation of antibody technologies. In April 2014, the company floated on the Alternative Investment Market (AIM) and has grown steadily since then.
The company’s current strategy is to continue to develop and grow by finding new or existing commercial assays (investigative procedures), for which improved antibodies may need to be identified. However, the company is competing against the global giants of the biotechnology world which have significant resources for antibody creation at their disposal.
Partner, Treena Turner, has worked closely with Bioventix since its MBO in 2003. She acts as Bioventix’s Finance Director providing technical and strategic advice to the management team. She was heavily involved in the company’s flotation on AIM and continues to prepare their bi-annual interim accounts and to oversee the audit.
Treena’s involvement in the business has been invaluable as she brings with her a wealth of experience. Her approach is very hands on and practical, and she managed all the financial reporting necessary to facilitate the company’s flotation on AIM. Her in- depth knowledge of the business, the management team and the industry sector itself is an enormous advantage as she is an integrated member of the team. Peter explains, “Having Treena has enabled the other directors to focus on the rest of the business. The AIM flotation was hard work and we couldn’t afford to take our eye off the ball in such a challenging market place. Our close working relationship with Treena and the level of trust that we have in her, gives us that extra confidence of knowing our financials are in good hands with our best interests at heart”.